| Tricida Inc (TCDA) | |||
|---|---|---|---|
| 0.108 0 (0%) | 01-23 16:00 | ||
| Open: | 0.1156 | Pre. Close: | 0.108 |
| High: | 0.116 | Low: | 0.0925 |
| Volume: | 31,125,310 | Market Cap: | 6(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 0.03 One year: 0.04 |
| Support: | Support1: 0.01 Support2: 0.01 |
| Resistance: | Resistance1: 0.03 Resistance2: 0.03 |
| Pivot: | 0.01  |
| Moving Averages: | MA(5): 0.01 MA(20): 0.02 MA(100): 0.15 MA(250): 6.23 |
| MACD: | MACD(12,26): -0.02 Signal(12,26,9): -0.02 |
| %K %D: | %K(14,3): 19.00 %D(3): 17.15 |
| RSI: | RSI(14): 27.09 |
| 52-Week: | High: 13.85 Low: 0.0411 Change(%): -99.8 |
| Average Vol(K): | 3-Month: 5831 10-Days: 276 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 0.01 - 0.01 | 0.01 - 0.01 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TCDA ] has closed above bottom band by 49.4%. Bollinger Bands are 99.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 85 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 55.11 |
| Shares Float (M) | 50.89 |
| % Held by Insiders | 8.01 |
| % Held by Institutions | 64.72 |
| Shares Short (K) | 10530 |
| Shares Short Prior Month (K) | 14000 |
| Stock Financials | |
|---|---|
| EPS | -5.293 |
| Book Value (p.s.) | 2.170 |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | -60.1 |
| Return on Equity (ttm) | |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | -2.249 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -108.79 |
| Levered Free Cash Flow (M) | -65.87 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | 0.01 |
| Price to Sales | |
| Price to Cash Flow | -0.01 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
